

Accepted Manuscript

Title: A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer

Authors: Stefano Coppola, Ilaria Carnevale, Erik H.J. Danen, Godefridus J. Peters, Thomas Schmidt, Yehuda G. Assaraf, Elisa Giovannetti



PII: S1368-7646(17)30027-4
DOI: <http://dx.doi.org/doi:10.1016/j.drup.2017.07.001>
Reference: YDRUP 604

To appear in: *Drug Resistance Updates*

Received date: 11-7-2017
Accepted date: 19-7-2017

Please cite this article as: Coppola, Stefano, Carnevale, Ilaria, Danen, Erik H.J., Peters, Godefridus J., Schmidt, Thomas, Assaraf, Yehuda G., Giovannetti, Elisa, A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. *Drug Resistance Updates* <http://dx.doi.org/10.1016/j.drup.2017.07.001>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer

Stefano Coppola ^{a,1}, Ilaria Carnevale ^{b,c,1}, Erik H.J. Danen ^d, Godefridus J. Peters ^b, , Thomas Schmidt ^{a,1}, Yehuda G. Assaraf ^e, Elisa Giovannetti ^{b,c,1*}

^a *Physics of Life Processes, Huygens-Kamerlingh Onnes Laboratory, Leiden University, Leiden, The Netherlands*

^b *Department of Medical Oncology, VU University Medical Center Amsterdam, Amsterdam, the Netherlands*

^c *Cancer Pharmacology Lab, AIRC Start-Up Unit, University Hospital of Pisa, Pisa, Italy*

^d *Division of Toxicology, LACDR, Leiden University, Leiden, The Netherlands*

^e *The Fred Wyszowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel*

* Corresponding author.

Elisa Giovannetti, MD, PhD

Cancer Pharmacology Lab, AIRC Start-Up Unit,

University Hospital of Pisa, Pisa, Italy

E-mail address: elisa.giovannetti@gmail.com

¹ These authors equally contributed to this work.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly chemoresistant malignancy. This chemoresistant phenotype has been historically associated with genetic factors. Major biomedical research efforts were concentrated that resulted in the identification of subtypes characterized by specific genetic lesions and gene expression signatures that suggest important biological differences. However, to date, these distinct differences could not be exploited for therapeutic

Download English Version:

<https://daneshyari.com/en/article/8436568>

Download Persian Version:

<https://daneshyari.com/article/8436568>

[Daneshyari.com](https://daneshyari.com)